Last $24.21 USD
Change Today 0.00 / 0.00%
Volume 0.0
TRUMY On Other Exchanges
As of 8:10 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

terumo corp-unspon adr (TRUMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/2/14 - $32.50
52 Week Low
05/1/14 - $19.68
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TERUMO CORP-UNSPON ADR (TRUMY)

Related News

No related news articles were found.

terumo corp-unspon adr (TRUMY) Related Businessweek News

No Related Businessweek News Found

terumo corp-unspon adr (TRUMY) Details

Terumo Corporation manufactures and sells medical products and equipment worldwide. The company operates through Cardiac & Vascular, General Hospital, and Blood Management segments. Its cardiac and vascular products primarily comprise interventional devices that include access devices, such as introducer sheaths, guidewires, and guiding catheters; therapeutic devices, which include balloon catheters and stents; intravascular imaging systems; and cardiopulmonary bypass systems comprising oxygenator with integrated arterial filters, heart-lung machines, and artificial thoracic vascular grafts. The company’s general hospital products principally include infusion systems, including infusion pumps, infusion solutions, IV catheter, and infusion line connectors; drug and devices comprising prefilled syringes and prefillable syringes; nutritional supplements; measuring devices systems with communication functions, such as blood glucose meters, blood pressure monitors, and thermometers; pain management medicines that include analgesic and antiemetic; and closed anticancer drug infusion systems. Its blood management products primarily comprise automated blood collection systems, blood bag systems with leukocyte reduction filters, automated blood component processing system, pathogen reduction technology systems, therapeutic apheresis systems, and cell expansion systems. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.

19,263 Employees
Last Reported Date: 06/25/14
Founded in 1921

terumo corp-unspon adr (TRUMY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

terumo corp-unspon adr (TRUMY) Key Developments

Terumo Receives CE Mark Approval for the Line Extension on Drug-Eluting Stent

Terumo Corporation announced that it continues to expand its portfolio and received CE Mark1 approval for line extension of its drugeluting stent, ‘Ultimaster’. With this product line extension there are now 48 items with a diameter ranging from 2.25 mm to 4 mm and lengths from 9 mm to 38 mm available. Following the clinical practice in interventional cardiology, the highly deliverable Ultimaster DES will be available with completed product portfolio to increase treatment option for wider range of lesions. Terumo expects to launch the new size 2.25 mm and further lengths of 33 mm and 38 mm for all stent diameters until fiscal year ending March 2015, following the full launch of the recently CEapproved Ultimaster DES. Since the launch Terumo has received extremely positive feedback from European physicians on the outstanding performance of this effective and easytouse stent system. Physicians benefit from the excellent deliverability, conformability, and flexibility of this product as it helps to provide safe and optimal outcomes for patients by maximizing efficiency.

Terumo Corporation Announces Earnings Results for the Six Months Ended September 30, 2014; Revised Earnings Guidance for the Third Quarter of Fiscal 2015; Provides Earnings Guidance for the Full Year Ending March 31, 2015

Terumo Corporation announced earnings results for the six months ended September 30, 2014. For the period, sales increased 3% to JPY 233.3 billion against JPY 17.8 million a year ago. Operating profit was JPY 33 billion, an 8% increase over the previous period of JPY 30.47 million. Ordinary income increased 15% to JPY 34 million from the previous period of JPY 29.6 million, but this includes a positive JPY 2.5 billion in foreign exchange effect. Net income saw a 12% increase and was JPY 21.9 million against JPY 19.4 million a year ago. Because tax rates were different in fiscal 2013 and fiscal 2014, and then higher for this period. Net income per diluted share was JPY 57.61 against JPY 51.24 a year ago. Comprehensive income attributable to shareholders of company was JPY 43.173 million against JPY 36.553 million a year ago. Income before income taxes and minority interests was JPY 34.081 million against JPY 28.258 million a year ago. For the third quarter, the company included a JPY 6.4 billion extraordinary loss in third quarter outlook. The JPY 4.0 billion effect that will remain after taxes will correct net income forecast down from JPY 37.5 billion to JPY 33.5 billion. For the full year ending March 31, 2015 the company expects net sales to be JPY 488 million, operating income of JPY 64 million and net income to be JPY 33.5 million or JPY 88.22 per share.

Terumo Eyes Acquisitions

Terumo Corporation (TSE:4543) is looking for acquisition opportunities. Yutaro Shintaku, President and Representative Director of Terumo, said, looking globally, the consolidation of our industry continues to progress. There have been three large acquisitions just recently. We have a long-term goal of being one of the world's ten largest medtech companies. As this industry consolidation continues, we need to think about how we can accelerate growth. We will continue to consider how we will do this, keeping acquisition firmly in mind as one method.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRUMY:US $24.21 USD 0.00

TRUMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CareFusion Corp $59.30 USD -0.30
Getinge AB kr204.30 SEK -1.00
Hospira Inc $63.43 USD -1.35
St Jude Medical Inc $65.87 USD -0.47
Teleflex Inc $109.56 USD -2.31
View Industry Companies

Industry Analysis


Industry Average

Valuation TRUMY Industry Range
Price/Earnings 28.6x
Price/Sales 2.2x
Price/Book 1.9x
Price/Cash Flow 28.6x
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TERUMO CORP-UNSPON ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at